Nuvama Wealth has initiated coverage on Park Medi World Ltd with a ‘Buy’ rating and target price of ₹280, citing strong hospital expansion and improving profitability. The stock is currently trading around ₹202, implying a potential 39% upside driven by bed capacity growth and rising healthcare demand in North India.
Author: Aditya Pareek | EQMint
Shares of Park Medi World Ltd are drawing investor attention after Nuvama Wealth initiated coverage on the hospital chain with a ‘Buy’ recommendation and a target price of ₹280 per share.
The brokerage report highlights strong growth potential for the company as it expands hospital capacity across North India and benefits from rising healthcare demand.
According to the research note, the stock is currently trading around ₹202, implying a potential 39% upside from current levels.
Park Medi World’s Expanding Hospital Network
Park Medi World operates a network of 14 multi-super-specialty hospitals with approximately 3,250 beds, including about 870 ICU beds, across states such as Haryana, Punjab, Delhi, and Rajasthan.
The hospital chain has been aggressively expanding its capacity to tap growing demand for affordable healthcare in North India.
According to the report, the company plans to expand its bed capacity to around 5,260 beds by FY28, driven by cluster-based expansion in key regions such as Haryana, Punjab, and NCR.
This growth strategy also includes entry into Uttar Pradesh, which is currently an underpenetrated healthcare market.
Rising Demand for Healthcare in Tier-II Cities
India’s healthcare sector is experiencing structural growth due to rising income levels, increasing insurance penetration, and higher awareness of medical services.
However, the country still faces a significant shortage of hospital beds, with around 1.5 beds per 1,000 people compared with the World Health Organization’s benchmark of 3 beds.
This gap is particularly evident in Tier-II and Tier-III cities, where healthcare infrastructure remains limited.
Park Medi World is focusing on these markets as part of its expansion strategy, positioning itself to benefit from rising demand outside major metropolitan areas.
Revenue and Profit Growth Outlook
Nuvama expects Park Medi World’s financial performance to improve significantly over the next few years.
Key projections include:
- Revenue CAGR: ~24% between FY25 and FY28
- EBITDA CAGR: ~20%
- Profit CAGR: ~28%
Revenue is expected to rise from ₹1,394 crore in FY25 to about ₹2,629 crore by FY28, supported by higher hospital occupancy and new facilities coming online.
Operating margins are expected to remain stable despite expansion as patient volumes increase.
Improved Specialty Mix Driving Profitability
Another key factor supporting growth is the company’s shift toward high-acuity specialties, including:
- Cardiology
- Neurology
- Oncology
These medical services typically generate higher revenue per patient.
The company’s average revenue per occupied bed (ARPOB) has already improved to around ₹27,406 per day, and analysts expect further increases as specialty services expand.
Benefit From Government Healthcare Schemes
Park Medi World has a strong presence in government healthcare programs such as:
- Central Government Health Scheme (CGHS)
- State Government Health Scheme (SGHS)
- PSU referral programs
Currently, government and PSU schemes contribute about 83% of the company’s revenue.
A 25–30% increase in CGHS reimbursement rates announced in October 2025 is expected to significantly boost hospital earnings.
Balance Sheet Strength After IPO
The company recently strengthened its financial position following its IPO.
It raised ₹770 crore through a fresh issue, with proceeds primarily used to repay debt and fund expansion projects.
As a result, the company is expected to turn net debt-free by FY26, improving financial stability and providing room for future growth investments.
Valuation and Stock Outlook
Despite its growth prospects, analysts note that Park Medi World still trades at a discount to other listed hospital chains in India.
The brokerage estimates the stock trades at around 13x FY28 EV/EBITDA, lower than peers in the healthcare sector.
As the company scales operations and improves profitability, analysts expect this valuation gap to narrow.
Conclusion
Park Medi World is emerging as one of the fastest-growing hospital platforms in North India.
With aggressive capacity expansion, improving specialty mix, and supportive industry tailwinds, analysts believe the company has strong long-term growth potential.
If execution remains on track, the stock could benefit from rising healthcare demand, operational efficiencies, and improved investor confidence.
For more such information visit EQMint
Disclaimer: This article is not an investment advice and is for educational purpose only
